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Abstract
Inﬂammation and cancer are related pathologies acting synergistically to promote tumor progres-
sion. In both, hematogenous metastasis and inﬂammation, P-selectin participates in interactions
involving tumor cells, platelets, leukocytes and endothelium. Heparin has been shown to inhibit
P-selectin and as a consequence it blunts metastasis and inﬂammation. Some heparin analogs
obtained from marine invertebrates are P-selectin inhibitors and do not induce bleeding effects.
The present work focuses on the P-selectin blocking activity of a unique heparan sulfate (HS) from
the bivalve mollusk Nodipecten nodosus. Initially, we showed that the mollusk HS inhibited LS180
colon carcinoma cell adhesion to immobilized P-selectin in a dose-dependent manner. In addition,
we demonstrated that this glycan attenuates leukocyte rolling on activated endothelium and inﬂam-
matory cell recruitment in thioglycollate-induced peritonitis in mice. Biochemical analysis indicated
that the invertebrate glycan also inhibits heparanase, a key player in cell invasion and metastasis.
Experimental metastasis of Lewis lung carcinoma cells was drastically attenuated by the mollusk
HS through a mechanism involving inhibition of platelet–tumor-cell complex formation in blood
vessels. These data suggest that the mollusk HS is a potential alternative to heparin for inhibiting
P-selectin-mediated events such as metastasis and inﬂammatory cell recruitment.
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Introduction
The relationship between cancer and inﬂammation has been increasing-
ly reported during the last decade (Coussens andWerb 2002).However,
the connection between these two pathologies was ﬁrst suggested ∼150
years ago (Balkwill andMantovani 2001).Whereas acute inﬂammation
is part of the organism defense response, chronic inﬂammation can lead
to cancer. Indeed, patients with ulcerative colitis and Crohn’s disease,
have a higher risk to develop colorectal cancer (Itzkowitz and Yio
2004). On the other hand, during hematogenous metastasis, natural
killer cells can attack tumor cells, decreasing the metastatic rate. Thus,
the function of leukocytes in tumor biology is complex (Lanca and
Silva-Santos 2012) and represents an attractive research area.
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Hematogenous metastasis and inﬂammatory cell recruitment
strongly depend on selectin function. P-selectin is a family member
of glycan-recognizing adhesion molecules. In endothelial cells,
P-selectin is stored in Weibel–Palade bodies, whereas in platelets it oc-
curs in α-granules. P-selectin is readily exposed at the surface of plate-
lets upon activation, mediating its interaction with leukocytes and
endothelial cells (Kansas 1996). Tumor cells are characterized by
aberrant glycosylation patterns (Altevogt et al. 1983; Kim et al.
1996), including the over-expression of highly branched or sialylated
oligosaccharides, especially fucosylated glycans, such as sialyl-LewisX
and sialyl-Lewisa. These glycans are ligands for selectins and their
presence is related to poor prognosis due to increased metastatic dis-
ease (Fukuoka et al. 1998; Tatsumi et al. 1998).
The metastatic process is comprised of several steps that include
degradation of basement membrane, entry of cancer cell into the
bloodstream, evasion of innate immune surveillance, adhesion to
the vascular endothelium of secondary sites with subsequent
extravasation and colonization. Once in the bloodstream, cancer
cells are covered by platelets, in a P-selectin-mediated process, form-
ing a natural barrier against immune system cells (Kim et al. 1998).
On the other hand, leukocytes recruitment during inﬂammation is
mediated by P- and L-selectins. These adhesion molecules are in-
volved in the ﬁrst steps of cellular recruitment by reducing the rolling
velocity of leukocytes, contributing to their adhesion and arrest at
sites of inﬂammation. In fact, P-selectin null mice exhibit reduced
platelet aggregation, delayed leukocyte recruitment and attenuated
metastasis, suggesting that P-selectin might be a common therapeut-
ic target to treat cancer-related inﬂammation (Mayadas et al. 1993;
Kim et al. 1998; Ludwig et al. 2007). The anticoagulant glycosami-
noglycan heparin is a potent inhibitor of P- and L-selectin binding
to their natural ligands (Nelson et al. 1993). Accordingly, heparin
treatment has been shown to reduce leukocyte recruitment and
metastasis through inhibition of P-selectin (Nelson et al. 1993;
Borsig et al. 2001).
Cancer patients have high-risk of developing thromboembolic
disease and therefore, heparin has been used as a prophylactic thera-
peutic agent. Retrospective analysis of patients under heparin therapy
revealed a better prognosis of the malignant disease, which has
not been associated with the anticoagulant effect of the drug (Kragh
et al. 2005; Stevenson et al. 2007). Several studies aimed to
investigate the anti-cancer effect of heparin revealed that it attenuates
experimental metastasis in animals (Borsig et al. 2001), mainly by
binding to P-selectin and decreasing the interaction between tumor
cells and platelets. Additionally, heparin can also attenuate metastasis
by inhibition of heparanase (Vlodavsky et al. 1994), the only known
mammalian endoglycosidase that cleaves heparan sulfate (HS) and is
over-expressed in essentially all human tumors. In fact, heparanase
over-expression correlates with poor prognosis in a variety of cancers
(Vlodavsky et al. 2012; Gomes et al. 2013).
We have previously shown that heparin analogues obtained from
marine invertebrate bind to P-selectin, attenuating metastasis, inﬂam-
mation and thrombosis (Borsig et al. 2007; Kozlowski et al. 2011). In
a recent study, we described a unique HS isolated from the bivalve
molluskN. nodosus (Figure 1). This sulfated polysaccharide is formed
by glucuronic acid and Glucosamine and can also contain a rare sulfa-
tion pattern on carbon 2 or 3 of the glucuronic acid units. We also de-
scribed that this compound was able to inhibit thrombus growth
without inducing bleeding effect (Gomes et al. 2010).
Although increasing evidence points to a beneﬁcial therapeutic ac-
tion of heparin in cancer patients, its bleeding effect still limits its use.
Here, we addressed the ability of HS from N. nodosus to attenuate
leukocyte recruitment and cancer metastasis. Our results revealed
that the mollusk HS effectively inhibits P-selectin activity, decreasing
the binding of carcinoma cells to P-selectin in vitro and its interaction
with platelets in vivo. The mollusk glycan also inhibits heparanase en-
zymatic activity in vitro. Moreover, we have demonstrated that this
glycan attenuates hematogenous metastasis and polymorphonuclear
cells recruitment in vivo.
Results
Nodipecten nodosus HS attenuates tumor cell binding
to P-selectin
Because P-selectin is a crucial mediator of cell–cell interactions during
inﬂammation and cancer, we evaluated whether HS from N. nodosus
could inhibit P-selectin. For this purpose, we analyzed the ability of
this compound to impair adhesion of LS180 cells to immobilized
P-selectin. It is known from previous work that this colon cancer cell
line expresses high content of selectin ligands (Mannori et al. 1995).
Nodipecten nodosus HS decreased tumor cell binding to P-selectin in
a dose-dependent manner, with an IC50 of 38.1 µg/mL. Heparin was
more efﬁcient in reducing tumor cell binding to P-selectin, showing
an IC50 of 24.5 µg/mL (Figure 2). It is worth mentioning that, because
heparin presents lower molecular weight (∼15 kDa) than N. nodosus
HS (∼30 kDa), the molar concentration of heparin is higher than that
of the mollusk HS. As expected, chondroitin sulfate did not inhibit
P-selectin binding to tumor cells, even at high concentrations.
Nodipecten nodosus HS reduces leukocyte rolling
and cell recruitment after inﬂammatory stimulus
While the involvement of inﬂammatory cells during several steps of
cancer progression is well documented, little is known about the
underlying mechanism. Because leukocyte rolling on activated endo-
thelium during inﬂammatory response is mediated by P-selectin, we
investigated how leukocyte rolling is affected by N. nodosus HS. Pre-
vious studies have shown that lipopolysaccharide (LPS) treatment in-
duces P-selectin upregulation in endothelial cells (Gotsch et al. 1994).
Based on that, we analyzed leukocyte rolling on LPS-activated endo-
thelium by intravital microscopy, before or after N. nodosus HS ad-
ministration. It was observed that treatment with the mollusk HS
inhibited LPS-induced leukocyte rolling to the basal level (Figure 3A
and Supplementary data). Because leukocyte rolling is the ﬁrst step
for cell recruitment, we further evaluated the effect N. nodosus HS on
a thioglycollate-induced peritonitis model in mice. After 3 h of inﬂam-
matory stimulus the peritoneal lavage was harvested and differential
Fig. 1. Nodipecten nodosus HS structure. Major disaccharide unit of the
N. nodosus HS.
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counting of leukocytes was performed. Figure 3B shows that thioglycol-
late promoted a signiﬁcant increase in the recruitment of polymorpho-
nuclear cells to the peritoneal cavity, compared with control. Whereas
treatment withN. nodosusHS resulted in a 50% reduction in leukocyte
recruitment mammalian heparin induced 60% of inhibition. This dif-
ference is not statistically signiﬁcant. Interestingly, treatment of P-sel−/−
mice with N. nodosus HS led to lower leukocyte recruitment in
comparison with both HS-treated wild-type or untreated P-sel−/−
mice (Figure 3C). These ﬁndings suggest an additional mechanism in-
volved in the inhibition of leukocyte recruitment by N. nodosus HS
besides P-selectin.
Nodipecten nodosus HS inhibits association between
tumor cells and platelets in vivo
As mentioned earlier in the introduction, P-selectin-dependent leuko-
cyte recruitment and intercellular interactions are crucial during in-
ﬂammation as well as during tumor metastasis. P-selectin-mediated
platelet association with tumor cells contributes to the success of me-
tastasis. In previous studies, we showed that glycosaminoglycans from
marine invertebrates could disrupt this association. In order to analyze
the ability of HS from N. nodusus to inhibit tumor cell–platelet inter-
actions in vivo, HS, heparin and chondroitin sulfate (8 mg/kg of each
glycan) was injected via tail vein 5–10 min before injection of Lewis
lung carcinoma (LLC) cells. The lungs were analyzed by immunoﬂuor-
escence 30 min after tumor cell (calcein labeled) injection.While in the
control group, ∼70% of tumor cells were associated with platelets
(Figure 4), tumor cell–platelet complex was reduced to 30% after N.
nodosus HS administration. Mammalian heparin attenuates tumor
cell–platelet association to a similar extent as observed in mice treated
with molluskHS. Chondroitin sulfate did not inhibit tumor cell–plate-
let association.
Mollusk HS inhibits heparanase and attenuates
experimental metastasis
LLC cells express high amounts of heparanase (Takahashi et al. 2005),
which plays a relevant role in tumor invasion andmetastasis (Ilan et al.
2006). Because heparanase has been pointed as a molecular target of
heparin in cancer, we wondered whether N. nodosus HS inhibits he-
paranase enzymatic activity. For this purpose, we used a naturally pro-
duced sulfate-labeled extracellular matrix (ECM) as substrate and
measured the release of HS degradation fragments upon incubation
with heparanase (Vlodavsky et al. 1983; Vlodavsky 2001). As
demonstrated in Figure 5, heparanase enzymatic activity was signiﬁ-
cantly inhibited by the mollusk HS. Because metastasis efﬁciency de-
pends on P-selectin and heparanase, and heparin treatment is known
to decrease tumor metastasis, we sought to assess the antimetastatic
activity of N. nodosus HS (Kim et al. 1998; Borsig et al. 2001). In
order to investigate that, we performed an experimental metastasis
model in mice, using LLC cells that express P-selectin ligands and he-
paranase. This experiment involved administration ofN. nodosusHS,
mammalian heparin and chondroitin sulfate (8 mg/kg of each glycan)
followed by injection (tail vein) of LLC carcinoma cells. Figure 6
shows the effect of the mollusk HS treatment on metastasis. Whereas
the number of metastatic foci was high in control lungs, HS-treated
animals presented just few metastatic foci. In other words, in control
animals we observed around 10 foci per lung while in mollusk
HS-treated animals an average of 1 focus per lung was detected.
We also noticed that the tumor burden (size) in control lungs was
markedly higher than in the treated animals. As expected, heparin
attenuates experimental metastasis, however at the same potency
observed in mice treated with mollusk HS. Injection of chondroitin
sulfate did not affect metastasis. Overall, these results indicate
that the mollusk HS may be an attractive therapeutic drug to
block both P-selectin-mediated interactions and heparanase activity,
blunting metastasis and inﬂammation without inducing bleeding
effects.
Discussion
Cell interactions among leukocytes, platelets and endothelium are
mediated by selectins and contribute to the pathophysiology of inﬂam-
mation and metastasis. Several studies have shown that heparin can
block these interactions and therefore attenuate hematogenous metas-
tasis and inﬂammatory cell recruitment. In 2010, we described a un-
ique HS obtained from the bivalve mollusk N. nodosus, which
presents 2 or 3 O-sulfation on glucuronic acid (Figure 1). This com-
pound is absent in the adductor muscle, and extracted from organs
commonly discarded during preparation for commercialization.
The mollusk glycan signiﬁcantly reduces experimental thrombus
growth in vivo without inducing any bleeding effect (Gomes et al.
2010). Therefore, we decided to investigate if this glycan could inhibit
P-selectin. In order to evaluate this inhibitory potential we performed
in vitro and in vivo experiments and showed that the mollusk
HS inhibits P-selectin interaction with colon carcinoma cell line
(LS180), decreases cell rolling and inﬂammatory cell recruitment.
Additionally it attenuates platelets–tumor cell association and hepar-
anase enzymatic activity, thereby blunting metastasis.
Leukocyte function in tumor biology has deserved attention
in cancer research (Mantovani et al. 2008; Alderton and Bordon
2012). It has been proposed that, in some types of cancer, the in-
ﬂammatory cascade is already activated before the tumor initiates
(Itzkowitz and Yio 2004). Conversely, in other situations the malig-
nant microenvironment promotes inﬂammatory cells recruitment,
which in turn can induce tumor growth (Pollard 2004; Sica et al.
2006) or lysis of tumor cells. Inﬂammatory leukocyte rolling on acti-
vated endothelium is a P-selectin mediated event. Applying intravital
microscopy, we showed that mollusk HS decreases leukocyte rolling
after endothelial cell activation (Figure 3A). We speculate that as a
Fig. 2. Nodipecten nodosus HS attenuates P-selectin binding to LS180 tumor
cells. Human colon carcinoma cells (LS180) adhesion to immobilized
P-selectin chimera was measured in the presence of increasing
concentrations of HS from N. nodosus (squares), unfractionated heparin
(circles) or chondroitin sulfate (triangles). The curves are representative of
three independent experiments. See the “Materials and methods” section
for experimental details.
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consequence of this inhibition, polymorphonuclear cells recruitment
to the peritoneal cavity was attenuated (Figure 3B). We also observed
a decrease in leukocyte recruitment in P-selectin deﬁcient mice
(Figure 3C). Because some glycosaminoglycans also bind to L-selectin,
inhibition of leukocyte recruitment through L-selectin interac-
tion could also be expected. Therefore, we suggest that HS from
N. nodosus might also inhibit L-selectin.
Another set of P-selectin-mediated interactions occurs during
dissemination of metastatic cancer cells. Along this process, into the
bloodstream, tumor cells are often covered with platelets in a
P-selectin-dependent manner. This interaction confers tumor cells
with physical shielding mediated by platelets, avoiding natural killer
cell-mediated tumor cell lysis. We found that the mollusk glycan sig-
niﬁcantly inhibited tumor-cell platelet association, as early as 30 min
after tumor cells injection (Figure 5). We suggest that without this
interaction tumor cells would be more vulnerable to immune surveil-
lance and, as a result, the metastasis rate would decrease. Using LLC
cells, which are carcinoma cells that express selectin ligands at the cell
surface (Brown et al. 2006), we demonstrated that the mollusk glycan
drastically attenuates seeding of tumor cells to the lungs. An elegant
Fig. 3. Nodipecten nodosus HS inhibitis leukocyte rolling and polymorphonuclear cell recruitment. (A) Leukocyte rolling (cells/min) along the endothelium of
postcapillary venules in distal ileum was measured by use of intravital microscopy. Four hours before counting, rats were intravenously injected with LPS
(0.5 mg/kg) or saline. In rats treated with LPS the leukocyte rolling was measured before and after intravenous administration of HS from N. nodusus (2 mg/kg).
(B) Wild-type (WT) mice were injected intraperitoneally with thioglycollate, followed by intravenous injection of mollusk HS, unfractionated heparin, chondroitin
sulfate (20 mg/kg of each glycan) or PBS 5 min later. Peritoneal lavage was harvested 3 h later. Cells were stained with hematoxylin and eosin and differentially
counted for mononuclear and polymorphonuclear cells. (C) Counting of polymorphonuclear cells in WT or P-sel−/− mice injected intraperitoneally with
thioglycollate, followed by injection of mollusk heparan sulfate. Scale bar represents 20 mm. The statistical signiﬁcance was determined by one-way analysis of
variance (ANOVA) or t-test (***P < 0.05).
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work of Labelle et al. (2011) showed that apart of protection from leu-
kocytes, platelets is also able to induce epithelial-mesenchymal transi-
tion in tumor cells via transforming growth factor beta (TGF-β)
mediated-mechanism and thereby promotes metastasis. Similarly,
through inhibition of platelet–tumor cell interaction the mollusk gly-
can may exert antimetastatic effect by suppressing the epithelial-
mesenchymal transition induced by platelets.
When tumor cells exit the bloodstream they need to degrade the
sub-endothelial basement membrane, which is rich in HS, in order
to colonize a secondary site (Liotta et al. 1980). Previous studies
have shown that heparin-mimicking compounds attenuate metastasis
by acting as heparanase inhibitors (Borsig et al. 2011). Therefore, we
suggest that the heparanase inhibitory activity of the mollusk glycan
contributes to the antimetastatic effect observed in our experiments.
Overall, the present work identiﬁes a new P-selectin inhibitor that
does not induce hemorrhagic effects observed in mammalian heparin.
We also showed that this compound attenuates thrombosis, inﬂamma-
tion and metastasis. Since cancer disease is usually associated with
thrombotic events we suggest that the mollusk HS is an attractive can-
didate to be a therapeutic drug for cancer-associated thrombosis and
cancer-related inﬂammation.
Materials and methods
Cell lines and reagents
Human colon carcinoma cells (LS180; ATCC, Manassas, VA)
were grown in minimum essential medium-α (MEM-α) (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen). Mouse LLC cells were grown in Dulbecco’s modiﬁed
Eagle’s medium (Vitrocell) supplemented with 10% FBS. All reagents
were from Sigma (St. Louis, MO), unless otherwise stated. Heparin
(Liquemine) was obtained fromRoche Pharma (Reinach, Switzerland).
Isolation of HS from N. nodosus
Adult specimens of the bivalve mollusk N. nodosus (Linnaeus 1778)
were collected from Baia da Ilha Grande, Angra dos Reis, Rio de
Janeiro, Brazil. The polysaccharides were extracted by protease diges-
tion and puriﬁed as described previously (Gomes et al. 2010).
Inhibition of tumor cell binding to immobilized P-selectin
The ability of glycosaminoglycans to inhibit the adhesion of
calcein acetoxymethyl (AM)-labeled LS180 cells to immobilized
P-selectin chimeras was investigated as described previously (Hostet-
tler et al. 2007). The glycans were tested in triplicate wells at each
concentration.
Intravital microscopy
Intravital microscopy was performed according to (Fortes et al. 1991)
with slight modiﬁcations. Leukocyte rolling in the mesenteric venules
was analyzed after 4 h of LPS (Sigma; 0.5 mg/kg) or phosphate-
buffered saline (PBS) intravenous injection. Adult male and female
Wistar rats (250 g body weight) were anesthetized with an intramus-
cular injection of 100 mg kg−1 of ketamine (Cristália, São Paulo,
Brazil) and 16 mg kg−1 of xylazine (Bayer AS, São Paulo, Brazil).
An abdominal midline incision (∼1.5 cm) was performed and the
mesentery was exposed for analysis. After positioning under the
microscope, a 30 min equilibration period preceded quantitative mea-
surements. The microscope used was a Zeiss Axio ImagerA1. Leuko-
cyte rolling was counted for 10 min. In the group that received
Fig. 4.Nodipecten nodosusHS inhibits platelet adhesion to tumor cells in vivo.
LLC cells labeled with calcein AM were intravenously injected via tail vein. (A)
Representative images of platelet–tumor cell association in the lungs of mice
injected with N. nodosus HS, unfractionated heparin, chondroitin sulfate
(8 mg/kg of each glycan) or PBS and euthanized 30 min later. Scale bars
represent 20 µm; (B) Numbers of platelet–tumor cell aggregates are
presented as percentages (in columns) of all counted tumor cells. The
statistical signiﬁcance of tumor cell–platelet association was determined by
ANOVA (***P < 0.05).
Fig. 5. Nodipecten nodosus HS is a heparanase inhibitor. The ability of the
mollusk HS to inhibit recombinant heparanase enzymatic activity was
determined as described in the “Materials and methods” section. Data are
representative of three independent experiments.
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LPS, leukocyte rolling was evaluated before and after circulation ofN.
nodosus HS for 5 min (2 mg/kg—intravenous injection). Videos are
available at Supplementary data. All animal work was performed ac-
cording to institutional guidelines for the use and care of experimental
animal, approved by the protocol number IBqM 014. Representative
videos of experimental groups are available as Supplementary data.
Thioglycollate-induced peritoneal inﬂammation
Micewere injected intraperitoneallywith 4% thioglycollate (1 mL). After
5 min, N. nodosus HS was administrated via tail vein injection. Mice
were sacriﬁced after 3 h and peritoneal lavage was collected using
4 mL ice-cold PBS, containing 3 mM Ethylenediamine tetraacetic acid
(EDTA) to prevent clotting. The peritoneal ﬂuid, 200 µL, was analyzed
Fig. 6. Experimental lung metastasis of LLC carcinoma cells is attenuated by mollusk HS treatment. Mice were intravenously injected with of PBS, mollusk HS,
heparin or chondroitin sulfate (8 mg/kg of each glycan) 10 min before injection of 106 LLC cells and terminated 21 days later. Metastatic foci in the lungs were
evaluated macroscopically. (A) Representative images of lungs harvested from mice injected with mollusk HS versus control. (B) Counting of metastatic foci.
The statistical signiﬁcance was determined by ANOVA.
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after cytospin preparation by hematoxylin and eosin staining. Then, dif-
ferential countingwas performed to evaluate the amount of polymorpho-
nuclear cells present in the peritoneal cavity. P-sel−/−and wild-type mice
were used in this experiment.
Tumor cell–platelets association in vivo
The formation of tumor cell–platelet complexwas performed as described
before (Borsig et al. 2001). Brieﬂy, LLC cells were harvested with 2 mM
EDTA in PBS, labeled with calcein AM, and injected intravenously into
mice with or without previous intravenous application of 200 µg of
N. nodosus HS. After 30 min, the lungs were harvested for analysis.
Lung sections were stained with goat anti-integrin αIIb (CD41) (Santa
Cruz biotechnology-sc6602), followed by anti-goat Cy3-conjugated anti-
body (Sigma), and analyzed by immunoﬂuorescence microscopy. The ex-
tent of platelet association with tumor cells was quantiﬁed by evaluating
calcein-labeled cells present in 40 ﬁelds of lung sections.
Heparanase enzymatic activity assay
Preparation of sulfate-labeled extracellular matrix (ECM)-coated
dishes and determination of heparanase enzymatic activity were per-
formed as previously described (Vlodavsky et al. 1983; Vlodavsky
2001). Brieﬂy, sulfate-labeled ECM coating the surface of 35-mm cul-
ture dishes was incubated (4 h, 37°C, pH 6.0) with constitutively ac-
tive recombinant human heparanase (120 ng/mL) in the absence or
presence of 5 μg/mL of mollusk HS, as described [18]. The incubation
medium containing sulfate-labeled degradation fragments was sub-
jected to gel ﬁltration on a Sepharose CL-6B column. Fractions
(0.2 mL) were eluted with PBS and their radioactivity counted in a
β-scintillation counter. HS degradation fragments were eluted at 0.5
<Kav < 0.8 (peak II, fractions 10–25).
Experimental metastasis model
Mice (8–10 weeks old) were intravenously injected with 106 LLC cells
via the tail vein. Nodipecten nodosus HS, heparin or chondroitin
(8 mg/kg of each glycan) administration was performed 10 min
prior to cell injection. Mice were sacriﬁced after 21 days. The lungs
were macroscopically evaluated for the number of metastatic foci.
Supplementary data
Supplementary data for this article is available online at http://glycob.
oxfordjournals.org/.
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AM, acetoxymethyl; ANOVA, analysis of variance; ECM, extracellu-
lar matrix; EDTA, Ethylenediamine tetraacetic acid; FBS, fetal bovine
serum; HS, heparan sulfate; Hep, unfractionated heparin; LLC, Lewis
lung carcinoma; LPS, lipopolysaccharide;MEM-α, minimum essential
medium-α; N. nodosus, Nodipecten nodosus; P-sel−/−, P-selectin-null
mice; PBS, phosphate-buffered saline; TGF-β, transforming growth
factor beta; WT, wild-type.
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